Cargando…

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses

Detalles Bibliográficos
Autores principales:	Schmiedeberg, Kristin, Vuilleumier, Nicolas, Pagano, Sabrina, Albrich, Werner C, Ludewig, Burkhard, Kempis, Johannes von, Rubbert-Roth, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547803/ https://www.ncbi.nlm.nih.gov/pubmed/34723209 http://dx.doi.org/10.1016/S2665-9913(21)00328-3

Ejemplares similares

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Anti‐SARS‐CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1?
por: Vuilleumier, Nicolas, et al.
Publicado: (2021)

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Pausing drugs and spacing vaccines: an open question – Authors' reply
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis
por: Haller, Christoph, et al.
Publicado: (2021)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history
por: Ota, Kenji, et al.
Publicado: (2023)

Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022)

Breast dose matters
por: Moadel, Renee M., et al.
Publicado: (2021)

Serological response following anti-SARS-CoV-2 vaccination in hematopoietic stem cell transplantation patients depends upon time from transplant, type of transplant and “booster”dose
por: Attolico, Immacolata, et al.
Publicado: (2022)

Socially optimal pandemic drug dosing
por: Strohbehn, Garth W, et al.
Publicado: (2021)

On finding minimal absent words
por: Pinho, Armando J, et al.
Publicado: (2009)

Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia?
por: Perner, Anders, et al.
Publicado: (2023)

The complexities of SARS-CoV-2 serology
por: Houlihan, Catherine F, et al.
Publicado: (2020)

The important role of serology for COVID-19 control
por: Winter, Amy K, et al.
Publicado: (2020)

Low-dose radiation, scientific scrutiny, and requirements for demonstrating effects
por: Møller, Anders Pape, et al.
Publicado: (2013)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Protein-based vaccine as the booster dose for adults: evidence and beyond
por: Shang, Lianhan, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

Hospital admissions due to COVID-19 in Scotland after one dose of vaccine
por: Dean, Natalie
Publicado: (2021)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

Tracking SARS-CoV-2 infection in India with serology
por: John, Jacob, et al.
Publicado: (2021)

In RRP, serologic response to HPV is frequently absent and slow to develop
por: Buchinsky, Farrel J., et al.
Publicado: (2020)

Minimal Absent Words in Prokaryotic and Eukaryotic Genomes
por: Garcia, Sara P., et al.
Publicado: (2011)

Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?
por: Iversen, Patrick L, et al.
Publicado: (2021)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment
por: Vaidya, Jayant S., et al.
Publicado: (2021)

Population serology for SARS-CoV-2 is essential to regional and global preparedness
por: Tian, Huaiyu, et al.
Publicado: (2020)

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
por: Rogawski McQuade, Elizabeth T, et al.
Publicado: (2021)

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
por: Hung, Ivan F N, et al.
Publicado: (2021)

Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies
por: Feng, Shuo, et al.
Publicado: (2023)

Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox?
por: Ogoina, Dimie, et al.
Publicado: (2023)

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses
por: Gounant, Valérie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7bglmrm745onsojuip4l3dfjaf